WednesdayApr 06, 2022 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions,…

Continue Reading

WednesdayApr 06, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Multiple Strong Market Paths

Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”) The company strategically partners with third-party organizations seeking to explore formulation opportunities with their specific APIs Lexaria is evaluating the effectiveness of various DehydraTECH-processed APIs, including CBD, nicotine, sildenafil, and more According to company CEO Chris Bunka, the management team is positioning the company to ensure that it has multiple paths to success In pursuit of multiple paths to success, Lexaria Bioscience (NASDAQ: LEXX), developer of the patented DehydraTECH(TM) drug delivery platform, strategically partners…

Continue Reading

MondayApr 04, 2022 9:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), Building a House of Brands, Is Creating World-Class Standards for Environmental Impact, Social Justice, and Corporate Governance, to Navigate Increasing Commoditization in its Market Segment

Red White & Bloom, a multi-state operator in cannabis and hemp-derived product lines, has built a platform to strengthen its brands, enabling it to wade through the difficulties of increasing product commoditization The company expects to showcase the results of the buildout process in the coming months RWB is also committed to fostering public and local input, equitable leadership opportunities, and removing systemic structures that marginalize segments of society A Boston Consulting Group (“BCG”) article entitled “Escaping the Doghouse: Winning in Commoditized Markets” notes that a company needs a clear roadmap that shows how it can reorganize itself for the…

Continue Reading

FridayApr 01, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Continues to Showcase Ability to Improve Effectiveness of Existing Drug Brands

Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules Lexaria continues to research DehydraTECH’s ability to improve the speed and bioavailability of cannabidiol (“CBD”) in treating high blood pressure and epileptic conditions The company continues its research demonstrating the ability of its technology -to enhance the performance of antiviral drugs and other active pharmaceutical ingredients Sublicensing DehydraTECH continues to create revenues for the company Lexaria has additionally pursued the use of its drug-enhancing technology, in partnership with sublicensees, for making adult-use recreational cannabis…

Continue Reading

ThursdayMar 31, 2022 9:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Continues to Focus on the Continued Growth of its Top-Line Revenue and Bottom-Line Results in a Move to achieve its 3-Year Success Plan

RWB’s mission has always been to become the superior and most recognizable cannabis company in the United States It seeks to achieve this by focusing on the continued growth of top-line revenue and bottom-line results through brand expansion, mergers, and acquisitions So far, in 2022, the company has announced the acquisition of PharmaCo, which sees the transfer of 21 medical and adult-use cannabis licenses RWB has also closed a lease assignment on a critical manufacturing/processing and distribution facility in Michigan Its management is confident that the foundations laid down so far will aid in the company’s growth going forward In…

Continue Reading

ThursdayMar 31, 2022 9:00 am

Hero Technologies Inc. (HENC) Subsidiary Establishes Presence in Booming Colorado Cannabis Market

Cannabis sales in Colorado broke another record last year, topping $2.22 billion in products sold Cannabis is “massive” driver of tax revenue for Colorado, raking in over $423 million last year alone HENC continues to pursue diversification and integration strategy through subsidiary Another record-breaking year for Colorado’s cannabis industry bodes well for Hero Technologies (OTC: HENC). The company anticipates expanding into the booming market via cultivation and dispensary operations through its wholly owned subsidiary, Mile High Green LLC.  Cannabis sales in the state broke another record last year, topping $2.22 billion in products sold, according to the Colorado Department of Revenue (https://cnw.fm/7lUaU). This…

Continue Reading

TuesdayMar 29, 2022 9:00 am

Hero Technologies Inc. (HENC) CEO Talks ‘Foot in the Door’ Acquisitions in Recent Bell2Bell Podcast

HENC is focusing on expansion of current operations, future growth in industry Company aims to be a low-cost, nationally and internationally branded company, become true multistate operator (“MSO”) Recent podcast provides overview of company’s strategic plans, important milestones Key acquisitions and investments have played an essential role in Hero Technologies’ (OTC: HENC)  strategic business plan and operations. As a featured guest during a recent episode of the Bell2Bell Podcast (https://ibn.fm/J3DGC), company CEO Gina Serkasevich discussed HENC’s careful expansion moves. In 2020, “both Highly Relaxing and the assets of V Brokers, under Veteran Hemp Co., were acquired,” said Serkasevich as she discussed…

Continue Reading

FridayMar 25, 2022 9:30 am

Flora Growth Corp. (NASDAQ: FLGC) Reaches Agreements Green-Lighting High-THC Cannabis Exports from Colombia, and Outlets for Premium CBD Skin Care Product in Asia

Cannabis product cultivator Flora Growth Corp. operates a premium growing facility in central Colombia and has received a growing list of authorizations to export its cannabis products for varied health and wellness purposes Flora Growth’s authorized distribution of low-THC CBD cannabis derivatives has been recently expanded to include a quota of up to 43,600 kg of products with high-THC cannabis Flora also reached agreement with Israel-based DNO Group to further commercialize Flora’s Mind Naturals skin care products through potential distribution outlets in Hong Kong, with plans to build into outlets in Israel and India later Colombia has also authorized the…

Continue Reading

TuesdayMar 22, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Phase of Epilepsy Research Using DehydraTECH(TM)-CBD

Lexaria’s patented DehydraTECH(TM) technology provides faster delivery times, increases bioavailability, increases brain absorption, improves drug potency, reduces administration costs, and masks unwanted flavors The epilepsy research will compare the FDA-approved Epidiolex(R) to the company’s proprietary DehydraTECH-CBD formulation The global cannabidiol (“CBD”) market had an estimated value of $2.7 billion in 2021 and is expected to reach $111.8 billion by 2030, driven by an increase in demand for CBD use in health and wellness industries Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW), a global innovator in drug delivery platforms, recently announced that the first phase of its epilepsy research program, EPIL-A21-1, has…

Continue Reading

MondayMar 21, 2022 9:15 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Intellectual Property Portfolio Grows Following Receipt of 24th Granted Patent

Lexaria has received a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof” The new patent, granted in Australia, is the first awarded from Lexaria’s 8th patent family and offers IP protection across a total of 9 claims Lexaria believes the patent could be meaningful as it seeks to build value With the new patent, Lexaria’s IP portfolio has now grown to 24 granted patents worldwide In his letter to shareholders dated January 27, 2022, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka documented the company’s expectation that it would receive additional patents in 2022. The expected…

Continue Reading

HempWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722